{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:37:22Z","timestamp":1777412242128,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed\/ refractory T\u2010cell lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A dose escalation study design was utilized. Primary and secondary endpoints included maximum tolerated dose (MTD), adverse events, and response rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six patients were treated with BV and two dose levels of lenalidomide, in 21\u2010day cycles. The protocol\u2010determined MTD was BV 1.8 mg\/kg and lenalidomide 25 mg, however, all patients required subsequent dose reductions with ongoing treatment. The most common adverse event was peripheral neuropathy in four of six patients. Two patients achieved complete responses and three achieved partial responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion:<\/jats:title><jats:p>The combination is deliverable with dose attenuation. Further study is needed to define clinical benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>This trial was registered on ClinicalTrials.gov (NCT number 03302728).<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70033","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:59:13Z","timestamp":1747148353000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T\u2010cell Lymphoma: Results of a Single\u2010centre Phase 1 Dose\u2010escalation Study"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9876","authenticated-orcid":false,"given":"Carrie","family":"van der Weyden","sequence":"first","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"},{"name":"Department of Biostatistics and Clinical Trials Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"Henry Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"7","key":"e_1_2_11_2_1","first-page":"1191","article-title":"The Outcome of Peripheral T\u2010cell Lymphoma Patients Failing First\u2010line Therapy: A Report From the Prospective","volume":"103","author":"Bellei M.","year":"2018","journal-title":"International T\u2010Cell Project Haematologica"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525915"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0198"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954460"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123801"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011894"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.07.004"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221074965"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:23:11Z","timestamp":1750684991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/jha2.70033"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70033","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"2024-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70033"}}